Targeting iron metabolism in drug discovery and delivery
| Autor: | Bart J Crielaard, Twan Lammers, Stefano Rivella |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
HUMAN HEPATOMA-CELLS Iron Hemoglobin Scavenger Receptor HYDROXYLASE DOMAIN PROTEIN-2 Pharmacology Biology Article AMYOTROPHIC-LATERAL-SCLEROSIS 03 medical and health sciences Drug Delivery Systems Iron homeostasis Neoplasms Drug Discovery METAL TRANSPORTER 1 Animals Homeostasis Humans Molecular Targeted Therapy AUTOSOMAL-DOMINANT HEMOCHROMATOSIS REPULSIVE GUIDANCE MOLECULE BONE MORPHOGENETIC PROTEIN Physiological control Drug discovery Neurodegenerative Diseases General Medicine Metabolism Human physiology 3. Good health TUMOR-ASSOCIATED MACROPHAGES BETA-THALASSEMIA-INTERMEDIA 030104 developmental biology Drug Design HEMOGLOBIN SCAVENGER RECEPTOR Clinical evaluation Haematological disorders |
| Zdroj: | Nature Reviews Drug Discovery |
| ISSN: | 1474-1776 |
| DOI: | 10.1038/nrd.2016.248 |
| Popis: | Iron fulfils a central role in many essential biochemical processes in human physiology, which makes proper processing of iron crucial. Although iron metabolism is subject to relatively strict physiological control, in recent years numerous disorders, such as cancer and neurodegenerative diseases, have been linked to deregulated iron homeostasis. Because of its involvement in the pathogenesis of these diseases, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents will likely have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are often available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink